Introduction
CRISPR-Cas9 and related gene-editing technologies have made it possible, for the first time, to precisely edit the human genome — including the germline edits that are inherited by future generations. In 2018, Chinese scientist He Jiankui announced the birth of gene-edited babies, triggering global ethical controversy. The debate about whether gene editing to eliminate hereditary diseases should be allowed sits at the intersection of science, medicine, disability rights, and bioethics.
Arguments for Allowing Gene Editing to Eliminate Hereditary Diseases
1. Preventing Serious Disease Is a Core Goal of Medicine
Medicine has always sought to prevent disease, and gene editing extends this mission to inherited conditions that cause severe suffering or premature death. Diseases like Huntington's, Tay-Sachs, severe combined immunodeficiency (SCID), and certain forms of sickle cell disease cause significant harm that current treatments cannot prevent. If gene editing can eliminate these conditions before they manifest — or before a life begins — the ethical case for doing so follows from the same logic that justifies all preventive medicine: reducing suffering is good.
2. Parents Already Make Genetic Choices Through Embryo Selection
Pre-implantation genetic diagnosis (PGD), used alongside IVF, already allows parents to screen embryos for genetic diseases and select unaffected ones for implantation. This is widely practiced and largely uncontroversial in medical ethics. The moral distinction between selecting an unaffected embryo (permitted) and editing an embryo to remove a disease-causing mutation (controversial) is philosophically thin — both result in a child without the disease. If the goal is ethically acceptable, the mechanism requires specific objection.
3. Regulatory Frameworks Can Prevent the Most Concerning Applications
The primary concern about permitting therapeutic gene editing is the "slippery slope" to enhancement — selecting for intelligence, height, or athletic ability. But these are different applications with different regulatory treatments. Medical gene editing aimed at serious monogenic diseases can be regulated differently from enhancement applications. The fact that a technology can be misused is not sufficient argument against its beneficial uses — the same logic would prohibit chemotherapy (which can be misused) or surgery. Targeted regulation can distinguish disease prevention from enhancement.
4. Germline Editing Could Eliminate Diseases Across Generations
Somatic gene editing (which affects only the treated individual) requires each patient to be treated separately. Germline editing, which modifies the genome in ways that are passed to offspring, could eliminate a hereditary disease from a family lineage permanently. For conditions like Huntington's — which causes progressive neurodegeneration and death in midlife with near-certain transmission to 50% of offspring — germline editing that eliminates the mutation would prevent not just one case but all future cases in that family. The multigenerational benefit is a powerful consequentialist argument.
5. Prohibiting the Technology Will Not Stop Its Development
He Jiankui's 2018 experiment demonstrated that a determined researcher can conduct germline gene editing in humans despite ethical guidelines. Prohibiting research in democratic countries with strong ethical oversight does not prevent the technology from advancing in jurisdictions with weaker regulation — it merely ensures that the most dangerous experiments occur without the safety standards and transparency that legitimate scientific institutions provide. Regulated development with clear ethical limits produces safer outcomes than prohibition that drives research underground or offshore.
Arguments Against Allowing Gene Editing to Eliminate Hereditary Diseases
1. Germline Edits Create Heritable Changes Without Consent
A person whose genome is edited as an embryo cannot consent to that modification — and neither can any of their descendants, who will carry the edited genome. This makes germline editing categorically different from other medical interventions: it is a permanent, heritable alteration made to a person and all of their biological future. Medical ethics requires informed consent for interventions; germline editing systematically violates this principle for all future persons carrying the edited genome. This is not a procedural objection but a fundamental one about the rights of future persons.
2. "Therapeutic" Editing and Enhancement Cannot Be Cleanly Separated
The distinction between disease elimination (acceptable) and enhancement (unacceptable) depends on a clear definition of disease — which does not exist in many cases. Deafness, short stature, and certain neurodivergent conditions are classified as disabilities by medical systems but as natural variation by many in those communities. Once gene editing for disease is normalized, the pressure to edit for other traits — intelligence, height, disease resistance — will intensify, and no bright line separates therapy from enhancement for contested conditions. The slippery slope concern is not hypothetical; it is inherent in the technology's logic.
3. Disability Rights Advocates Warn of Eugenic Implications
Many disability rights scholars and advocates argue that gene editing to eliminate genetic conditions expresses and reinforces a devaluation of lives lived with those conditions. If society invests in technology to prevent the birth of people with Down syndrome, sickle cell, or deafness, it implicitly communicates that those lives are less valuable. The history of 20th century eugenics — in which scientific justifications were used to eliminate "undesirable" traits — creates an obligation to scrutinize current genetic intervention technologies with particular care for how they define which lives are worth living.
4. Off-Target Edits and Long-Term Effects Are Unknown
CRISPR gene editing has been shown to produce unintended edits at non-target genomic locations — "off-target effects" that could have unpredictable consequences. In germline editing, these effects would be inherited. The long-term consequences of specific edits — including interactions between edited and unedited genes that only manifest across generations — cannot be predicted or tested in advance. He Jiankui's experiment produced edits with unclear consequences that could manifest decades later. The precautionary principle requires that a technology with multigenerational, irreversible effects meet a higher safety standard than current science can verify.
5. Access Would Be Unequal, Creating Genetic Stratification
Gene editing technologies will initially be expensive, complex, and available only at advanced medical centers. If permitted, their availability will track existing wealth and healthcare inequalities: wealthy families will be able to eliminate hereditary disease risks; poor families will not. Over generations, this could produce a society where health, and potentially other genetic traits, increasingly diverge along class lines — with affluent populations editing out disease vulnerabilities while disadvantaged populations accumulate them. This genetic stratification would compound existing inequality in a novel and particularly irreversible way.